Stockcalc – Free Trial
Have a free look inside the StockCalc website at www.stockcalc.com
I have used the analysis tools on the website stockcalc.com to generate some of the content of this blog post. These tools and reports are available for free at www.stockcalc.com/TopPicks.aspx.
Fully Valued Stocks on NASDAQ
Today we are looking at companies that are considered fully valued based on the Analyst data in the StockCalc database.
In this table we can see the close price and target price for these companies along with the number of analysts covering the stock. We also have included the fiscal year for the target price as sometimes these analyst targets are not for the current or even the next fiscal year.
There can be a number of reasons why a company would be on this list. What is particularly interesting are companies with a large analyst following that make this list. We need to dig deeper into these companies to understand why the difference in price versus target.
Today’s Data on NASDAQ
Today’s data is for companies listed on the NASDAQ.
| Symbol | Name | Target Year | Close Price | Target Price Mean | Currency | Target Price # of Estimates |
|---|---|---|---|---|---|---|
| NFLX | Netflix Inc | 2018 | 300.690000 | 272.7500 | USD | 12 |
| NKTR | Nektar Therapeutics Inc | 2018 | 104.510000 | 78.5000 | USD | 2 |
| IDXX | IDEXX Laboratories Inc | 2018 | 190.900000 | 181.6667 | USD | 3 |
| ANSS | Ansys Inc | 2018 | 157.050000 | 149.0000 | USD | 2 |
| DBX | Dropbox Inc | 2018 | 29.900000 | 22.0000 | USD | 1 |
| DISCB | Discovery Inc | 2018 | 35.950000 | 26.6667 | USD | 6 |
| IEP | Icahn Enterprises LP | 2018 | 56.780000 | 45.0000 | USD | 1 |
| MKTX | MarketAxess Holdings Inc | 2018 | 217.280000 | 190.0000 | USD | 1 |
| CACC | Credit Acceptance Corp | 2018 | 328.760000 | 272.5000 | USD | 2 |
| UBNT | Ubiquiti Networks Inc | 2018 | 68.860000 | 55.0000 | USD | 1 |
| CMPR | Cimpress NV | 2019 | 158.150000 | 139.5000 | USD | 2 |
| TREE | LendingTree Inc | 2018 | 347.900000 | 331.0000 | USD | 4 |
| URBN | Urban Outfitters Inc | 2019 | 36.140000 | 28.0000 | USD | 1 |
| KLXI | KLX Inc | 2019 | 69.180000 | 55.0000 | USD | 1 |
| SFLY | Shutterfly Inc | 2018 | 82.170000 | 73.0000 | USD | 1 |
| BCPC | Balchem Corp | 2018 | 80.620000 | 60.0000 | USD | 1 |
| MANT | Mantech International Corp | 2018 | 54.390000 | 47.0000 | USD | 1 |
| NAVG | Navigators Group Inc | 2018 | 57.700000 | 45.0000 | USD | 1 |
| SYNA | Synaptics Inc | 2019 | 45.480000 | 36.0000 | USD | 1 |
| ENTA | Enanta Pharmaceuticals Inc | 2018 | 81.840000 | 59.0000 | USD | 1 |
| WING | Wingstop Inc | 2018 | 47.440000 | 40.0000 | USD | 1 |
| MNTA | Momenta Pharmaceuticals Inc | 2018 | 17.250000 | 10.0000 | USD | 1 |
| PTCT | PTC Therapeutics Inc | 2018 | 31.920000 | 21.5000 | USD | 2 |
| SPSC | SPS Commerce Inc | 2018 | 62.060000 | 54.2500 | USD | 4 |
| AMNB | American National Bankshares Inc | 2018 | 38.150000 | 10.0000 | USD | 1 |
Let’s look at a few companies…
Lets look at a couple of the companies on this list to get a better understanding of them.
NFLX:NAS Netflix
http://www.netflix.com
Netflix has 5500 employees and is headquartered in United States.
Netflix Inc provides multimedia content through the internet. It provides a subscription based platform for television shows, movies and original series.
NKTR:NAS Nektar Therapeutics
http://www.nektar.com
Nektar Therapeutics has 509 employees and is headquartered in United States.
Nektar Therapeutics Inc is a biopharmaceutical company engaged in the development of new molecules to treat diseases with unmet medical needs. The company is researching and developing drugs for treating cancer, auto-immune disease and chronic pain.
Free Valuation
Run a valuation on any of the companies listed above at www.stockcalc.com/valureport.aspx or subscribe at our Stockcalc Facebook Page to receive this list each day Stockcalc Reports.
The content presented here is in part from the website stockcalc.com and is provided on an as is or as available basis with all faults and may not be current in all cases. You should not rely on any of the information as authoritative or as a substitute for the exercise of your own skill and judgment in making an investment decision.